IP Library › Granted Patent US 12,668,841
Granted Patent B2
US 12,668,841 · App. 18/972,253 · Granted Jun 30, 2026

In situ sequencing of RNA transcripts with non-uniform 5′ ends

Inventors: Cynthia Hao (Saratoga, CA); Max R. Salick (San Francisco, CA); Ci Chu (Palo Alto, CA)
Assignee: Insitro, Inc.
C12Q1/6874C12Q1/6841C12Q1/6853
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,668,841
App. No.
18/972,253
Filed
Dec 6, 2024
Granted
Jun 30, 2026
Kind
B2
Art Unit
1683
USPC
435/6.11
Abstract

Disclosed herein are methods for performing in situ sequencing of RNA transcripts with non-uniform 5′ ends. During reverse transcription (RT) of RNA transcripts, RT enzyme is induced to “template-switch” to a separate oligonucleotide provided as the template for the upstream flanking region. This flanking region is grafted onto the beginning of the cDNA, enabling padlock probe detection, rolling circle amplification, and fluorescent in situ sequencing. Overall, the disclosed method for in situ sequencing can be applicable for analyzing exogenously introduced transcripts (e.g., identifying and determining impact of a perturbation including a CRISPR perturbation or shRNA/siRNA/ASO perturbation), analyzing naturally occurring transcripts (e.g., measuring gene expression, detecting splicing events), and analyzing modified, naturally occurring transcripts (e.g., detecting mutations or gene edits).

Claims (38)

1 . A construct for performing a rolling circle amplification reaction, the construct comprising:

an RNA transcript from a transfected cell, wherein the RNA transcript comprises a complementary sequence of a padlock arm sequence; and

a cDNA strand, wherein the cDNA strand is hybridized with the RNA transcript and is reverse transcribed from the RNA transcript,

wherein the cDNA strand comprises:

a template switching oligonucleotide (TSO) arm sequence;

a poly C sequence; and

a padlock arm sequence, wherein the transfected cell comprises the padlock arm sequence and is produced by inserting the padlock arm sequence into a genome of a cell using one of a construct of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), a cDNA construct, a Transcription Activator-like Effector Nuclease (TALEN), and a Zinc finger nuclease; and

an RNA template switching oligonucleotide (TSO) comprising a poly G sequence,

wherein the RNA transcript is transcribed from the genome of the transfected cell

wherein the poly G sequence is hybridized to the poly C sequence of the cDNA strand, and wherein a portion of the RNA TSO is hybridized to the TSO arm sequence of the cDNA strand.

2 . The construct of claim 1 , wherein the cDNA strand further comprises a barcode sequence which encodes for a guide RNA (gRNA) that guides a CRISPR protein to a target site in genomic DNA of a cell.

3 . The construct of claim 1 wherein the poly C sequence comprises 2 to 5 cytosine nucleobases.

4 . The construct of claim 1 , wherein the poly G sequence comprises 2 to 5 guanine nucleobases.

5 . The construct of claim 1 , wherein the RNA TSO comprises one or more locked nucleic acids (LNAs).

6 . The construct of claim 5 , wherein the RNA TSO comprises one locked nucleic acid (LNA) at a 3′ end of the RNA TSO.

7 . The construct of claim 5 , wherein 1% to 50% of the nucleotides of the RNA TSO comprise LNAs.

8 . The construct of claim 1 , wherein the RNA transcript further comprises a reverse transcription priming site.

9 . The construct of claim 8 , wherein the cDNA strand further comprises a sequence complementary to the reverse transcription priming site.

10 . The construct of claim 1 , wherein the RNA transcript is an RNA polymerase III-transcribed RNA transcript.

11 . The construct of claim 1 , wherein the RNA transcript further comprises a target sequence, and wherein the cDNA strand further comprises a reverse complement of the target sequence.

12 . The construct of claim 1 , wherein the TSO arm sequence is located at a 3′ end of the cDNA strand.

13 . A construct for performing a rolling circle amplification reaction, the construct comprising:

an RNA transcript from a transfected cell, wherein the RNA transcript comprises a complementary sequence of a padlock arm sequence; and

a cDNA strand, wherein the cDNA strand is hybridized with the RNA transcript and is reverse transcribed from the RNA transcript,

wherein the cDNA strand comprises:

a template switching oligonucleotide (TSO) arm sequence;

a poly C sequence; and

a padlock arm sequence, wherein the transfected cell comprises the padlock arm sequence and is produced by inserting the padlock arm sequence into a genome of a cell such that the padlock arm sequence is located in a genome of the transfected cell at a position located less than 100 nucleobases downstream of an RNA polymerase II or RNA polymerase III promoter; and

an RNA template switching oligonucleotide (TSO) comprising a poly G sequence,

wherein the RNA transcript is transcribed from the genome of the transfected cell

wherein the poly G sequence is hybridized to the poly C sequence of the cDNA strand, and wherein a portion of the RNA TSO is hybridized to the TSO arm sequence of the cDNA strand.

14 . The construct of claim 13 , wherein the cDNA strand further comprises a barcode sequence which encodes for a guide RNA (gRNA) that guides a CRISPR protein to a target site in genomic DNA of a cell.

15 . The construct of claim 13 , wherein the poly C sequence comprises 2 to 5 cytosine nucleobases or wherein the poly G sequence comprises 2 to 5 guanine nucleobases.

16 . The construct of claim 13 , wherein the RNA TSO comprises one or more LNAs.

17 . The construct of claim 16 , wherein the RNA TSO comprises one LNA at a 3′ end of the RNA TSO.

18 . The construct of claim 16 , wherein 1% to 50% of the nucleotides of the RNA TSO comprise LNAs.

19 . The construct of claim 13 , wherein the RNA transcript further comprises a reverse transcription priming site, and wherein the cDNA strand further comprises a sequence complementary to the reverse transcription priming site.

20 . The construct of claim 13 , wherein the RNA transcript further comprises a target sequence, and wherein the cDNA strand further comprises a reverse complement of the target sequence.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 18, 2024
From: HAO, CYNTHIA; SALICK, MAX R.; CHU, CI
To: INSITRO, INC.
Reel/Frame 069624/0630 →
Continuity (3)
Division 18210970 · Jun 16, 2023
Provisional Application 63353119 · Jun 17, 2022
Related Publication 20250101513A1 · Mar 27, 2025
References Cited (46)
US 11046952B2 · Blainey et al. · 2021 [cited by applicant]
US 11214797B2 · Regev et al. · 2022 [cited by applicant]
US 11345932B2 · Stoner et al. · 2022 [cited by applicant]
US 11421270B2 · Feldman et al. · 2022 [cited by applicant]
US 11421273B2 · Askary et al. · 2022 [cited by applicant]
US 11535865B2 · Feldman et al. · 2022 [cited by applicant]
US 11560561B2 · Lim et al. · 2023 [cited by applicant]
US 20110021369A1 · Mhlanga et al. · 2011 [cited by applicant]
US 20140315245A1 · Yam · 2014 [cited by examiner]
US 20180365372A1 · Araya et al. · 2018 [cited by applicant]
US 20190024075A1 · Gourguechon et al. · 2019 [cited by applicant]
US 20190161751A1 · Kaas et al. · 2019 [cited by applicant]
US 20190203281A1 · Robins et al. · 2019 [cited by applicant]
US 20200017852A1 · Lee · 2020 [cited by applicant]
US 20200190513A1 · Fernandez · 2020 [cited by examiner]
US 20200248184A1 · Joung et al. · 2020 [cited by applicant]
US 20200283843A1 · Regev et al. · 2020 [cited by applicant]
US 20210115436A1 · Ramenani et al. · 2021 [cited by applicant]
US 20210163926A1 · Labaer et al. · 2021 [cited by applicant]
US 20210164039A1 · Wang et al. · 2021 [cited by applicant]
US 20210340527A1 · Blainey et al. · 2021 [cited by applicant]
US 20220010367A1 · Ramachandran Iyer et al. · 2022 [cited by applicant]
US 20220064633A1 · Wei et al. · 2022 [cited by applicant]
US 20220155281A1 · Victors et al. · 2022 [cited by applicant]
US 20220229044A1 · Feldman et al. · 2022 [cited by applicant]
US 20220325300A1 · Stoner et al. · 2022 [cited by applicant]
US 20220396833A1 · Askary et al. · 2022 [cited by applicant]
US 20220411850A1 · Feldman et al. · 2022 [cited by applicant]
WO 2019113499A1 · 2019 [cited by applicant]
WO 2019222284A1 · 2019 [cited by applicant]
WO 2021091611A1 · 2021 [cited by applicant]
WO 2022178522A1 · 2022 [cited by applicant]
Lee, J., et al. “Fluorescent in situ sequencing (FISSEQ) of RNA for gene expression profiling in intact cells and tissues”, Nature Protocols, 10(3), p. 442 (2015). [cited by applicant]
Feldman, D., et al., “Lentiviral co-packaging mitigates the effects of intermolecular recombination and multiple integrations in pooled genetic screens”, BioRxiv online publication Feb. 8, 2018. [cited by applicant]
Feldman, D., et al., “Optical Pooled Screens in Human Cells”, Cell. Oct. 17, 2019, 179(3), p. 787-799. [cited by applicant]
Feldman, D., et al., “Pooled genetic perturbation screens with image-based phenotypes”, Nature Protocols Feb. 2022; 17(2), p. 476-512. [cited by applicant]
Dixit, A., et al., “Perturb-Seq: Dissecting Molecular Circuits with Scalable Single-Cell RNA Profiling of Pooled Genetic Screens”, Cell. Dec. 15, 2016, 167(7), p. 1853-1866. [cited by applicant]
Ye, C., et al., “DRUG-seq for miniaturized high-throughput transcriptome profiling in drug discovery”, Nature Communications, 9, 4307 (2018). [cited by applicant]
Radtke, A., et al., “IBEX: an iterative immunolabeling and chemical bleaching method for high-content imaging of diverse tissues”, Nature Protocols, 17, pp. 378-401 (Jan. 2022). [cited by applicant]
Peng, X., et al. “Coupling oligonucleotides possessing a poly-cytosine tag with magnetic ionic liquids for sequence-specific DNA analysis” The Royal Society of Chemistry. 2018; p. 2, 95 second column, last paragraph; Ta… [cited by applicant]
International Search Report and Written Opinion for PCT/US23/68577, received Nov. 8, 2023, 28 pages. [cited by applicant]
Mignardi, M., et al., “Fourth-generation sequencing in the cell and the clinic”, Genome Medicine 2014, 6:31. [cited by applicant]
Picelli, S., et al., “Full-length RNA-seq from single cells using Smart-seq2”, Nature Protocols, vol. 9, No. 1, 2014, pp. 171-181. [cited by applicant]
Ramsköld, D., et al., “Full-Length mRNA-Seq from single cell levels of RNA and individual circulating tumor cells”, Nat Biotechnol. Aug. 2012; 30(8): 777-782. [cited by applicant]
Hagemann-Jensen, et al., “Single-cell RNA counting at allele and isoform resolution using Smart-seq3”, Nature Biotechnology, vol. 38, Jun. 2020, pp. 708-714. [cited by applicant]
Picelli, S., et al., “Smart-seq2 for sensitve full-length transciptome profiling in single cells”, Nature Methods, vol. 10, No. 11, Nov. 2013, pp. 1096-1100. [cited by applicant]